Stefanetti, Giuseppe (2014) THE IMPACT OF SALMONELLA POLYSACCHARIDE ANTIGENS STRUCTURE AND CONJUGATION CHEMISTRY ON NTS GLYCOCONJUGATE VACCINES. [Tesi di dottorato]

[img]
Preview
Text
Giuseppe Stefanetti - PhD Thesis.pdf

Download (4MB) | Preview
[error in script] [error in script]
Item Type: Tesi di dottorato
Lingua: English
Title: THE IMPACT OF SALMONELLA POLYSACCHARIDE ANTIGENS STRUCTURE AND CONJUGATION CHEMISTRY ON NTS GLYCOCONJUGATE VACCINES
Creators:
CreatorsEmail
Stefanetti, Giuseppestefanetti.g@gmail.com
Date: 26 March 2014
Number of Pages: 113
Institution: Università degli Studi di Napoli Federico II
Department: Scienze Chimiche
Scuola di dottorato: Biotecnologie
Dottorato: Scienze biotecnologiche
Ciclo di dottorato: 26
Coordinatore del Corso di dottorato:
nomeemail
Sannia, Giovannisannia@unina.it
Tutor:
nomeemail
Sannia, GiovanniUNSPECIFIED
Micoli, FrancescaUNSPECIFIED
Date: 26 March 2014
Number of Pages: 113
Uncontrolled Keywords: Vaccines, Glycoconjugates, Nontyphoidal Salmonella, Carbohydrates
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/11 - Biologia molecolare
Aree tematiche (7° programma Quadro): SALUTE e TUTELA DEL CONSUMATORE > Biotecnologie, strumenti e tecnologie generiche per la salute umana
Date Deposited: 08 Apr 2014 11:05
Last Modified: 15 Jul 2015 01:01
URI: http://www.fedoa.unina.it/id/eprint/9658

Abstract

The Novartis Vaccines Institute for Global Health (NVGH) is working on the development of a bivalent glycoconjugate vaccine against nontyphoidal Salmonellae (NTS) covering the main serovars S. Typhimurium and S. Enteritidis causing invasive disease in Africa. The vaccine is based on the conjugation of the lipopolysaccharide O antigen, the main surface polysaccharide of NTS, with CRM197 as carrier protein. In this contest, my PhD project has been focused in three related aspects: 1) Structural and biological characterization of NTS O antigen purified from different S. Typhimurium and S. Enteritidis strains. 2) Synthesis, characterization and immunological evaluation of a panel of NTS glycoconjugate vaccine variants (OAg source, conjugation chemistry, OAg/protein ratio) to better understand the key factors in glycoconjugate vaccine design required for optimal antibody-mediated immunity. 3) Design of new efficient glycoconjugation methodologies which allow the synthesis of structurally highly-defined glycoconjugate vaccines and simplify the conjugation process.

Actions (login required)

View Item View Item